

Shahnaz-Shak
762926

=> dis his

(FILE 'HOME' ENTERED AT 08:33:07 ON 24 JUL 2002)

FILE 'REGISTRY' ENTERED AT 08:33:17 ON 24 JUL 2002

E BASB024/CN
E OUTER MEMBRABE PROTEIN/CN
E OUTER MEMBRANE PROTEIN/CN 5

=> s e263-283

1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS GENE LPDA)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS GENE OMP-85)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 520 GENE PORA CLASS I)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 575 GENE PORA CLASS I)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 800580 GENE PORA CLASS I)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 830248 GENE PORA CLASS I)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 900278 GENE PORA CLASS I)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 900974 GENE PORA CLASS I)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 901005 GENE PORA CLASS I)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN A:N.T.:P1 .16 GENE PORA FRAGMENT)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN HH GENE OMP85)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE HLYD)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE NMA0086)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE NMA0178)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE NMA0296)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE NMA0440)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE NMA1729)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE NMA2124)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE NMA2132)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE NSPA)"/CN
1 "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS)"/CN
L1 20 ("OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS GENE LPDA)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS GENE OMP-85)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 520 GENE PORA CLASS I)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 575 GENE PORA CLASS I)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 800580 GENE PORA CLASS I)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 830248 GENE PORA CLASS I)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 900278 GENE PORA CLASS I)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 900974 GENE PORA CLASS I)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN 901005 GENE PORA CLASS I)"/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN A:N.T.:P1.16 GENE PORA

FRAGMENT) "/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN HH GENE OMP85) "/CN OR "OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN Z2491 GENE HLYD)"

=> fil medl,hcap,biosis,embase,jicst,wplids	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	85.90	86.11

FILE 'MEDLINE' ENTERED AT 08:36:26 ON 24 JUL 2002

FILE 'HCAPLUS' ENTERED AT 08:36:26 ON 24 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:36:26 ON 24 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 08:36:26 ON 24 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 08:36:26 ON 24 JUL 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'WPLIDS' ENTERED AT 08:36:26 ON 24 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

=> s 11 or outer membrane protein(1)neisser? meningitid?
L2 402 FILE MEDLINE
L3 373 FILE HCAPLUS
L4 371 FILE BIOSIS
L5 294 FILE EMBASE
L6 0 FILE JICST-EPLUS

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

EXCEEDS MAXIMUM FIELD LENGTH, WILL BE SEARCHED AS 'OUTER MEMBRANE PROTEIN (NEISSERIA MENINGITIDIS STRAIN/CN'

ADDITIONAL TERMS EXCEED MAXIMUM FIELD LENGTH ''

L7 30 FILE WPIDS

TOTAL FOR ALL FILES

L8 1470 L1 OR OUTER MEMBRANE PROTEIN(L) NEISSE? MENINGITID?

=> s 18 and (basb024 or basb 024)

L9 0 FILE MEDLINE

L10 1 FILE HCAPLUS

L11 0 FILE BIOSIS

L12 0 FILE EMBASE

L13 0 FILE JICST-EPLUS

L14 0 FILE WPIDS

TOTAL FOR ALL FILES

L15 1 L8 AND (BASB024 OR BASB 024)

=> d cbib abs

L15 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2002 ACS

2000:145035 Document No. 132:204077 Sequence and diagnostic and prophylactic and therapeutic applications for **Basb024 outer membrane protein of Neisseria meningitidis**. Thonnard, Joelle (SmithKline Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2000011182 A1 20000302, 103 pp.

DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP5989 19990813. PRIORITY: GB 1998-18004 19980818.

AB The invention provides **BASB024** polypeptides and polynucleotides encoding **BASB024** polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. Serotyping is also discussed. Vaccine compns. are also described that are formulated from this **BASB024** peptide.

=> s (basb024 or basb 024) and (amino acid or immunogen? fragment or polypeptide)
and (insert? or delet? or addition?) and sequence?

L16 0 FILE MEDLINE
L17 0 FILE HCPLUS
L18 0 FILE BIOSIS
L19 0 FILE EMBASE
L20 0 FILE JICST-EPLUS
L21 0 FILE WPIDS

TOTAL FOR ALL FILES

L22 0 (BASB024 OR BASB 024) AND (AMINO ACID OR IMMUNOGEN? FRAGMENT OR
POLYPEPTIDE) AND (INSERT? OR DELET? OR ADDITION?) AND SEQUENCE?

=> s (basb024 or basb 024) and (amino acid or immunogen? fragment or polypeptide or
sequence?) and (insert? or delet? or addition?)

L23 0 FILE MEDLINE
L24 0 FILE HCPLUS
L25 0 FILE BIOSIS
L26 0 FILE EMBASE
L27 0 FILE JICST-EPLUS
L28 0 FILE WPIDS

TOTAL FOR ALL FILES

L29 0 (BASB024 OR BASB 024) AND (AMINO ACID OR IMMUNOGEN? FRAGMENT OR
POLYPEPTIDE OR SEQUENCE?) AND (INSERT? OR DELET? OR ADDITION?)

=> s (basb024 or basb 024) and (amino acid or immunogen? fragment or polypeptide or
sequence? or insert? or delet? or addition?)

L30 0 FILE MEDLINE
L31 1 FILE HCPLUS
L32 0 FILE BIOSIS
L33 0 FILE EMBASE
L34 0 FILE JICST-EPLUS
L35 1 FILE WPIDS

TOTAL FOR ALL FILES

L36 2 (BASB024 OR BASB 024) AND (AMINO ACID OR IMMUNOGEN? FRAGMENT OR
POLYPEPTIDE OR SEQUENCE? OR INSERT? OR DELET? OR ADDITION?)

=> dup rem 136

PROCESSING COMPLETED FOR L36

L37 1 DUP REM L36 (1 DUPLICATE REMOVED)

=> d cbib abs

L37 ANSWER 1 OF 1 HCPLUS COPYRIGHT 2002 ACS DUPLICATE 1
2000:145035 Document No. 132:204077 Sequence and diagnostic and
prophylactic and therapeutic applications for Basb024 outer
membrane protein of Neisseria meningitidis. Thonnard, Joelle (SmithKline
Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2000011182 A1
20000302, 103 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB,
BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,
DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,
TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP5989 19990813.
PRIORITY: GB 1998-18004 19980818.

AB The invention provides BASB024 polypeptides and
polynucleotides encoding BASB024 polypeptides and
methods for producing such polypeptides by recombinant

techniques. Also provided are diagnostic, prophylactic and therapeutic uses. Serotyping is also discussed. Vaccine compns. are also described that are formulated from this **BASB024** peptide.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	50.71	136.82
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.86	-1.86

STN INTERNATIONAL LOGOFF AT 08:49:17 ON 24 JUL 2002

=> fil medl,hcap,biosis,embase,jicst,wplids;s thonnard, j?/au,in
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 08:50:20 ON 24 JUL 2002

FILE 'HCAPLUS' ENTERED AT 08:50:20 ON 24 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:50:20 ON 24 JUL 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 08:50:20 ON 24 JUL 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'JICST-EPLUS' ENTERED AT 08:50:20 ON 24 JUL 2002
COPYRIGHT (C) 2002 Japan Science and Technology Corporation (JST)

FILE 'WPIDS' ENTERED AT 08:50:20 ON 24 JUL 2002
COPYRIGHT (C) 2002 THOMSON DERWENT

'IN' IS NOT A VALID FIELD CODE
L1 25 FILE MEDLINE
L2 66 FILE HCAPLUS
L3 34 FILE BIOSIS
'IN' IS NOT A VALID FIELD CODE
L4 27 FILE EMBASE
L5 0 FILE JICST-EPLUS
L6 45 FILE WPIDS

TOTAL FOR ALL FILES
L7 197 THONNARD, J?/AU, IN

=> s 17 and (basb024 or basb 024 or neisser? meningit? or meningococ? or meningit?)
L8 0 FILE MEDLINE
L9 12 FILE HCAPLUS
L10 1 FILE BIOSIS
L11 0 FILE EMBASE
L12 0 FILE JICST-EPLUS
L13 10 FILE WPIDS

TOTAL FOR ALL FILES
L14 23 L7 AND (BASB024 OR BASB 024 OR NEISSER? MENINGIT? OR MENINGOCOC?
OR MENINGIT?)

=> dup rem 114
PROCESSING COMPLETED FOR L14
L15 13 DUP REM L14 (10 DUPLICATES REMOVED)

=> d 1-13 cbib abs

L15 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 1
2002:107146 Document No. 136:166052 Vaccine composition. Berthet,
Francois-Xavier Jacques; Dalemans, Wilfried; Denoel, Philippe; Dequesne,
Guy; Feron, Christiane; Garcon, Nathalie; Lobet, Yves; Poolman, Jan;
Thiry, Georges; Thonnard, Joelle; Voet, Pierre (Smithkline
Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2002009746 A2
20020207, 125 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA,

BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF,
BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU,
MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.
APPLICATION: WO 2001-EP8857 20010731. PRIORITY: EP 2000-956369 20000731;
GB 2001-3170 20010208.

AB The present invention relates to the field of vaccine formulation, particularly the field of novel adjuvant compns. comprising outer membrane vesicles (or blebs), and advantageous methods of detoxifying these compns., and advantageous methods of use of such adjuvants. The novel adjuvant for Gram-neg. bacterial vaccine is a capsular polysaccharide or detoxified lipid A portion of LPS derived from engineered *Neisseria meningitidis* serogroup A, B, Y or W; *Hemophilus influenzae*; *Streptococcus pneumoniae*; or *Moraxella catarrhalis*. These engineered bacteria have reduced or switched off expression of one or more gene selected from htrB, msbB, ppxK, pmrA, pmrB, pmrE, pmrF, galE, siaA, siaB, siaC, siaD, ctrA, ctrB, ctrC and ctrD. Vaccines comprising the adjuvant and pathogen-derived antigen is esp. useful for protecting elderly patients against the pathogen.

L15 ANSWER 2 OF 13 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
2002:331035 Document No.: PREV200200331035. Outer membrane vesicles and other options for a **meningococcal B** vaccine. Poolman, J. T. (1); Feron, C. (1); Dequesne, G. (1); Denoel, P. A. (1); Dessoix, S. (1); Goraj, K. K. (1); Janssens, D. E. (1); Kummert, S. (1); Lobet, Y. (1); Mertens, E. (1); Monnom, D. Y. (1); Momin, P. (1); Pepin, N. (1); Ruelle, J.-L. (1); Thonnard, J. J. (1); Verlant, V. G. (1); Voet, P. (1); Berthet, F. X. (1). (1) SmithKline Beecham Biologicals S. A, Rue de l'Institut 89, B-1330, Rixensart: Jan.POOLMAN@sbbio.be Belgium. Ferreiros, Carlos [Editor]; Criado, Maria Teresa [Editor]; Vazquez, Julio [Editor]. (2002) pp. 135-149. Emerging strategies in the fight against meningitis: Molecular and cellular aspects. Edition 1. print. Publisher: Horizon Scientific Press Wymondham, Norfolk, NR18 0EH, UK. ISBN: 1-898486-34-4 (cloth). Language: English.

L15 ANSWER 3 OF 13 HCPLUS COPYRIGHT 2002 ACS
2002:222707 Outer membrane vesicles and other options for a **meningococcal B** vaccine. Poolman, J. T.; Feron, C.; Dequesne, G.; Denoel, P. A.; Dessoix, S.; Goraj, K. K.; Janssens, D. E.; Kummert, S.; Lobet, Y.; Mertens, E.; Monnom, D. Y.; Momin, P.; Pepin, N.; Ruelle, J.-L.; Thonnard, J. J.; Verlant, V. G.; Voet, P.; Berthet, F. X. (UK). Emerging Strategies in the Fight against Meningitis, 135-149. Editor(s): Ferreiros, Carlos; Criado, Maria Teresa; Vazquez, Julio. Horizon Scientific Press: Wymondham, UK. ISBN: 1-898486-34-4 (English) 2002. CODEN: 69CKED.

AB The development of a menB vaccine is difficult. Outer membrane vesicles derived from wild-type strains were found to be protective in teenagers in homologous settings. From Brazilian studies evidence has been obtained that protection > 4 yr can be obsd. with a monovalent wild-type OMV vaccine even in epidemiol. situations characterized by multi-strain endemic disease. With such OMV vaccines, the serum bactericidal activity (SBA) results demonstrate serosubtype (PorA) specificity, particularly in infants. Ongoing research has identified potential cross-bactericidal activity inducing menB antigens. This research has recently been supplemented by the possibility to identify antigens from available full genomic sequences. The challenge is to find the right combination of antigens in order to develop a generic crossreactive menB vaccine.

L15 ANSWER 4 OF 13 HCPLUS COPYRIGHT 2002 ACS DUPLICATE 2

2001:101328 Document No. 134:146387 Immuno-protective and non-toxic Gram-neg. bleb vaccine suitable for pediatric use. Berhet, Francois-xavier Jacques; Dalemans, Wilfried L. J.; Denoel, Philippe; Dequesne, Guy; Feron, Christiane; Lobet, Yves; Poolman, Jan; Thiry, Georges; Thonnard, Joelle; Voet, Pierre (Smithkline Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2001009350 A2 20010208, 128 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP7424 20000731. PRIORITY: GB 1999-18319 19990803.

AB The present invention relates to an immuno-protective and non-toxic Gram-neg. bleb vaccine suitable for pediatric use. Examples of the Gram-neg. strains from which the blebs are made are *N. meningitidis*, *M. catarrhalis* and *H. influenzae*. The blebs of the invention are improved by one or more genetic changes to the chromosome of the bacterium, including up-regulation of protective antigens, down-regulation of immunodominant non-protective antigens, and detoxification of the Lipid A moiety of LPS.

L15 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 3
2000:573939 Document No. 133:160576 Protein and DNA sequences of *Neisseria* gene BASB064 and their uses in diagnosis and vaccination. Thonnard, Joelle (Smithkline Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2000047743 A1 20000817, 79 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP888 20000204. PRIORITY: GB 1999-2937 19990210.

AB The invention provides BASB064 polypeptides and polynucleotides encoding BASB064 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. The invention provides protein and DNA sequences of *Neisseria meningitidis* gene BASB064, and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

L15 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 4
2000:535283 Document No. 133:130816 Protein and DNA sequences of *Neisseria* gene BASB059 and their uses in diagnosis and vaccination. Thonnard, Joelle (Smithkline Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2000044904 A1 20000803, 77 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP561 20000125. PRIORITY: GB 1999-2070 19990129.

AB The invention provides protein and DNA sequences of *Neisseria meningitidis* gene BASB059, and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

L15 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 5
2000:535269 Document No. 133:130815 Immunogenic protein BASB058 and its gene from **Neisseria meningitidis**. **Thonnard, Joelle**

(Smithkline Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2000044890 A1 20000803, 79 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP560 20000125. PRIORITY: GB 1999-2084 19990129.

AB The invention provides BASB058 polypeptides and polynucleotides from **Neisseria meningitidis** serogroup B strain ATCC 13090 encoding BASB058 polypeptides and methods for producing such polypeptides by recombinant techniques. The BASB058 gene encodes a 107-amino acid protein with no similarities to known proteins. Also provided are diagnostic, prophylactic and therapeutic uses of BASB058 proteins, nucleic acids, and antibodies for **Neisseria meningitidis** infections.

L15 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 6
2000:513807 Document No. 133:132401 An antigen of **Neisseria meningitidis** similar to the RlpB protein of Escherichia coli and its diagnostic and therapeutic uses. **Thonnard, Joelle**
(Smithkline Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2000043518 A1 20000727, 79 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP427 20000119. PRIORITY: GB 1999-1465 19990122; GB 1999-2077 19990129.

AB The invention provides **Neisseria meningitidis** BASB056 polypeptides and polynucleotides encoding BASB056 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses thereof. The protein was manufd. by expression of the cloned gene in Escherichia coli. Mice inoculated with the purified antigen mounted a strong response to it. The antigen was detectable in convalescent serum of **meningitis** patients.

L15 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 7
2000:513806 Document No. 133:130803 Cloning of protein Basb055 gene from **Neisseria meningitidis** and its therapeutic use.
Thonnard, Joelle (Smithkline Beecham Biologicals S.A., Belg.).
PCT Int. Appl. WO 2000043517 A1 20000727, 82 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP425 20000119. PRIORITY: GB 1999-1462 19990122; GB 1999-2069 19990129.

AB The invention provides protein BASB055 and its cDNA from **Neisseria** (N.)

meningitidis and methods for producing the protein products by recombinant techniques. Methods of prepg. vaccines using protein BASB055 antigenic fragments and their antibody for diagnostic, prophylactic and therapeutic uses are also provided.

L15 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 8
2000:493682 Document No. 133:115925 **Neisseria** BASB antigens and genes and their use in diagnosis and vaccination. Ruelle, Jean-Louis; **Thonnard, Joelle** (SmithKline Beecham Biologicals S.A., Belg.).
PCT Int. Appl. WO 2000042191 A2 20000720, 129 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP135 20000110. PRIORITY: GB 1999-952 19990115; GB 1999-838 19990115; GB 1999-1945 19990128; GB 1999-1948 19990128; GB 1999-2078 19990129; GB 1999-2088 19990129; GB 1999-2074 19990129; GB 1999-2879 19990209; GB 1999-2936 19990210; GB 1999-3978 19990220; GB 1999-4133 19990223; GB 1999-4404 19990225.

AB The invention provides **N. meningitidis** BASB antigens and genes and methods for producing BASB antigens with recombinant organisms. Also provided are diagnostic, prophylactic and therapeutic uses. Thus, BASB051 showed similarity to **N. gonorrhoeae** ComL lipoprotein, BASB057 to **N. gonorrhoeae** MtrE outer membrane lipoprotein, BASB061 to **N. meningitidis** Mlp protein, BASB066 to **N. meningitidis** CtrA protein, and BASB071 to **N. gonorrhoeae** HisJ protein. BASB060, BASB063, BASB065 antigens and genes are also reported.

L15 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 9
2000:145035 Document No. 132:204077 Sequence and diagnostic and prophylactic and therapeutic applications for **Basb024** outer membrane protein of **Neisseria meningitidis**. **Thonnard, Joelle** (SmithKline Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2000011182 A1 20000302, 103 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-EP5989 19990813. PRIORITY: GB 1998-18004 19980818.

AB The invention provides **BASB024** polypeptides and polynucleotides encoding **BASB024** polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses. Serotyping is also discussed. Vaccine compns. are also described that are formulated from this **BASB024** peptide.

L15 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2002 ACS
2000:608907 Document No. 133:188909 Protein and DNA sequences of haemophilus influenzae gene BASB070 and their uses in diagnosis and vaccination. Ruelle, Jean-Louis; **Thonnard, Joelle** (Smithkline Beecham Biologicals S.A., Belg.). PCT Int. Appl. WO 2000050599 A1 20000831, 97 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG,

KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 2000-EP1423 20000222. PRIORITY: GB 1999-4183 19990224.

AB The invention provides protein and DNA sequences of *haemophilus influenzae meningitidis* gene BASB070, and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.

L15 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2002 ACS DUPLICATE 10
1999:708915 Document No. 131:333044 Protein and DNA sequences of
Neisseria meningitidis BASB006 gene, and uses thereof in
vaccine compositions and in assays for the diagnosis of bacterial
infections. Thonnard, Joelle (Smithkline Beecham Biologicals S.
A., Belg.). PCT Int. Appl. WO 9955873 A2 19991104, 103 pp. DESIGNATED
STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU,
CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE,
BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT,
LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2.
APPLICATION: WO 1999-EP2766 19990420. PRIORITY: GB 1998-8866 19980424.

AB This invention provide's the sequence of the *Neisseria meningitidis* BASB006 gene, which encodes a protein that has homol. to the Hap protein of *Haemophilus influenzae*. The invention also relates to the use of an immunogenic fragment, preferably the extracellular domain, of the provided protein in a vaccine. The invention further relates to the use of the provided protein and/or gene in the diagnosis of bacterial infections, esp. those of *Neisseria*.

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	37.37	37.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.43	-7.43

STN INTERNATIONAL LOGOFF AT 08:51:31 ON 24 JUL 2002